Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered adenoviral vectors to achieve cell- and tissue-specific delivery, and tunable expression of genes and regulators with unprecedented precision.
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $30M
Founded date: 2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.08.2022 | Series A | $30M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| 12.08.2022 | Vector BioPharma becomes operational with $30 million series... | Based on the research of Andreas Plückthun, a pioneer in the field of protein engineering and prof... | startuptic... |